For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How does the forecasted CAGR of the luveris industry compare to other sectors?
The luveris market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to an increasing number of fertility clinics, rise in healthcare expenditure, growth in the use of personalized medicine, increasing prevalence of obesity, and increasing urbanization
The luveris market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the rising prevalence of infertility in both men and women, the rising prevalence of hormonal disorders, the rising incidence of obesity, growing investments in fertility research, and increasing genetic screening. Major trends in the forecast period include technological advancements, assisted reproductive technology, advancements in hormone therapy, personalized medicine, and integration of artificial intelligence.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20151&type=smp
What market trends are acting as primary growth drivers for the luveris sector?
The rising infertility rates are expected to propel the growth of the luveris market going forward. Infertility rates refer to the percentage of couples or individuals who are unable to conceive after a certain period of trying, typically measured over a year of unprotected intercourse. Increasing infertility rates are attributed to factors such as delayed childbearing, lifestyle choices, environmental pollutants, and underlying health conditions. Luveris (lutropin alfa) is used to treat infertility in women with low levels of luteinizing hormone (LH) by stimulating ovulation and promoting the development of eggs in the ovaries. For instance, in July 2024, according to the Human Fertilization and Embryology Authority, a UK-based regulator of fertility treatment and research, approximately 52,500 patients underwent in vitro fertilization (IVF), and 3,000 received donor insemination (DI) treatment at Human Fertilization and Embryology Authority (HFEA) licensed fertility centers in the UK in 2022. The number of IVF cycles, including fresh and frozen embryo transfers, rose to 77,000 in 2022, marking an 11% increase from 69,000 in 2019. Therefore, the rising infertility rates will drive the growth of the luveris market.
What are the fastest-growing segments in the luveris market forecast period?
The luveris market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Intravenous), Pre-Filled Syringes
2)By Indication: Treatment Of Hypogonadotropic Hypogonadism, Ovulation Induction, Assisted Reproductive Technology
3) By Route of Administration: Subcutaneous Injection, Intramuscular Injection
4) By Patient Demographics: Adult Female Patients, Adult Male Patients, Couples Undergoing Fertility Treatments
5) By End User: Hospitals, Fertility Clinics, Specialty Pharmacies, Home Healthcare Providers
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/luveris-global-market-report
How are emerging trends transforming the luveris market dynamics?
The key trend in the luveris market is adopting a strategic investment approach for the development and manufacture of novel medicines. Strategic investments are investments made with the goal of achieving long-term business objectives, such as gaining a competitive advantage, expanding market share, or enhancing operational capabilities. For instance, in April 2024, Merck KGaA, a Germany-based science and technology company, invested $316 million (€300 million) in a brand-new research facility at its international headquarters in Darmstadt, Germany. The advanced research center will focus on developing solutions for manufacturing antibodies, mRNA applications, and other products essential for biotechnological production within Merck’s Life Science business sector. This center will consolidate research on key technologies, including raw materials and processes for the production of antibodies, recombinant proteins, and viral vectors. Additionally, the center will advance research in cell culture media, pharmaceutical formulation and purification aids, digital reference materials, and the further development of analytical chromatography, a method for separating, identifying, and quantifying chemical substances. Research along the mRNA value chain will also be conducted at the new facility.
Which major players hold significant market share in the luveris sector?
Major companies operating in the luveris market include Merck KGaA
Which regional segments are forecasted to witness the fastest growth in the luveris market?
North America was the largest region in the luveris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luveris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Luveris Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20151
Need Customized Data On Luveris Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20151&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
